US$34 million in emergency financing will provide access to vaccines for over 2 million people in Lebanon
Vaccines
Scientists are monitoring a coronavirus mutation that could affect the strength of vaccines
As scientists try to track the spread of a new, more infectious coronavirus variant around the world — finding more cases in the United States and elsewhere this week — they are also keeping an eye on a different mutation with potentially greater implications for how well Covid-19 vaccines work.
NIH neuroscientists isolate promising mini antibodies against COVID-19 from a llama
National Institutes of Health researchers have isolated a set of promising, tiny antibodies, or “nanobodies,” against SARS-CoV-2 that were produced by a llama named Cormac.
Pregnant women in third trimester unlikely to pass SARS-CoV-2 infection to newborns
Pregnant women who are infected with SARS-CoV-2, the virus that causes COVID-19, during the third trimester are unlikely to pass the infection to their newborns, suggests a study funded by the National Institutes of Health.
Two billion COVID vaccine doses secured, WHO says end of pandemic is in sight
The huge vaccine reservoir means that COVAX, a 190-country international initiative that seeks to ensure all countries have equal access to coronavirus vaccines, can plan to start delivering the shots in the first quarter of 2021
Why we’re giving $250 million more to fight COVID-19
In the pandemic’s first year, the work of ending the pandemic was confined to a relatively small domain: Labs and clinical trials
Statement from NIH and BARDA on the FDA Emergency Use Authorization of the Moderna COVID-19 Vaccine
The U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) to Moderna, Inc., a biotechnology company based in Cambridge, Massachusetts, for its COVID-19 vaccine, which was co-developed with scientists at the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID).
